FinVector Vision Therapies Overview
Company Headquarters: Kuopio, Finland
Founded: 1997
Workforce: 100+
Company Working:
FinVector Vision Therapies was previously known as Ark Therapeutics Limited and it is a major player in the market which is involved in research and development of viral-based gene therapy products. The company develops and manufactures products used for gene therapy through its manufacturing facility which is approved by European Medicines Agency(EMA). It offers services and viral-based product types, including Adenoviral, AAV, and Lentiviral-based vectors. The company operates in business segments namely, cell banking and viral seed stocks, R&D cell/gene therapy unit, platform process development / scale up, assay development and analytical testing, cGMP Manufacturing capabilities, FinVector aseptic filling capability, stability studies, Viral Vectors (including Adeno, AAV, Lenti), and Others.
Strategy
FinVector Vision Therapies focuses on producing quality products that can be used for manufacturing of final products by customers. Also, the company is looking forward to producing final products under its own brand. Moreover, the company is focusing establishing long term agreements with major players in the market to generate maximum revenue. FinVector Vision Therapies is well-known for research and development of the products and has strong pipeline related to the gene therapy.
